Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new bispecific antibody is changing the game for relapsed myeloma. In the phase 3 CERVINO trial, etentamig nearly doubled response rates and cut the risk of disease progression by 60% compared to standard therapies in triple-class exposed relapsed/refractory multiple myeloma. Notably, a simplified dosing regimen eliminated grade 3+ cytokine release syndrome, opening the door for outpatient and community-based treatment.
A bispecific antibody is reshaping treatment for relapsed multiple myeloma. Results from the phase 3 CERVINO trial, presented at the 2026 International Myeloma Society Annual Meeting, show that etentamig — a BCMA x CD3 bispecific T-cell engager given monthly — significantly outperformed investigator's choice of standard available therapies (SAT) in patients with triple-class exposed relapsed/refractory multiple myeloma.
The efficacy data are striking. Etentamig achieved an overall response rate of 74% vs. 45.7% with SAT, and the median progression-free survival (PFS) was not reached with etentamig compared to just 6.2 months with SAT. The PFS benefit held across subgroups, including older patients (≥75 years) and those treated at non-academic centers — a meaningful signal for real-world applicability.
By the Numbers:
Why it matters: Etentamig's simplified step-up dosing — which eliminated high-grade cytokine release syndrome — could make this therapy accessible beyond academic centers, potentially transforming how and where patients with relapsed myeloma receive care.
